The Safety of HMG-CoA Reductase Inhibitors in Special Populations at High Cardiovascular Risk
The DOI matches its Crossref record; 281 of the 286 references it cites were found in a registry or an index.
Abstract
Controlled clinical studies and clinical experience over many years have proven that virtually all patients benefit from lipid-lowering therapy with statins, even those with normal LDL cholesterol levels. Several recent large outcome trials have further demonstrated the clinical benefits and safety of statins in patients with a wide-range of high risks for cardiovascular disease. Those patients at highest absolute cardiovascular risk generally have the most to gain from statin therapy. A variety of statins are available to lower plasma lipids to guideline levels, but all differ in their pharmacokinetic properties, drug interaction profiles, and risk of myotoxicity. This has been highlighted by the withdrawal of cerivastatin from the market as a result of serious safety concerns. This review examines the safety and effectiveness of statins in special populations at high risk of cardiovascular disease-patients with coronary heart disease, dyslipidaemia, diabetes, hypertension, nephrotic disease, HIV, organ transplant patients and the elderly-with a focus on clinically relevant differences in the properties of individual statins that may influence the risk of drug interactions and side effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several factors including female sex, ethnicity, multisystem disease, and small body frame predispose to SAMS (see Box 1), with the presence of an increasing number of factors associated with greater risk.9,30,32–34”
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162 · cited 5×
“Furthermore, in hypercholesterolemic patients with CAD, 12-week treatment with fluvastatin 40 mg twice daily improved myocardial perfusion, especially in areas of ischaemia [101]; similar beneficial effects on myocardial perfusion have also been demonstrated with simvastatin and pravastatin [102,103].”
BackgroundInfluentialBrown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
The progression from hypertension to congestive heart failure
Levy, D. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530440037034 · Cited by 2,155 · cited 1×
“Hypertension is the most common treatable risk factor for cardiovascular disease and heart failure [157], and is often found alongside other disorders such as dyslipidaemia, obesity and insulin resistance in a condition known as metabolic syndrome.”
BackgroundThompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463 · cited 2×
“Indeed, the incidence of myopathy has been reported to increase over 10-fold when some statins are co-administered with gemfibrozil [25,32], niacin [29,33,34], warfarin [29,33], digoxin [29], erythromycin [29,35], itraconazole [30,36] and cyclosporine [19,26,34,37,38].”
BackgroundResultThe ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2998 · Cited by 1,331
Wood, D., De Backer, G., Faergeman, O., Graham, I., Mancia, G., & Pyörälä, K. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)90209-x · Cited by 1,255
Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
LaRosa, J. C., He, J., & Vupputuri, S. (1999) · JAMA · doi:10.1001/jama.282.24.2340 · Cited by 1,246
Second Joint Task Force of European (1998) · European Heart Journal · doi:10.1053/euhj.1998.1243 · Cited by 1,131
Adherence with statin therapy in elderly patients with and without acute coronary syndromes
Jackevicius, C. A. (2002) · JAMA · doi:10.1001/jama.288.4.462 · Cited by 1,077
Hypertriglyceridemia as a cardiovascular risk factor
Austin, M. A., Hokanson, J. E., & Edwards, K. L. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00031-9 · Cited by 1,066
Rendic, S., & Carlo, F. J. D. (1997) · Drug Metabolism Reviews · doi:10.3109/03602539709037591 · Cited by 949
Wacher, V. J., Wu, C., & Benet, L. Z. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940130302 · Cited by 857
Grunfeld, C. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.74.5.1045 · Cited by 848
Jukema, J. W., Bruschke, A. V. G., van Boven, A. J., Reiber, J. H. C., Bal, E. T., Zwinderman, A. H., Jansen, H., Boerma, G. J. M., van Rappard, F. M., & Lie, K. I. (1995) · Circulation · doi:10.1161/01.cir.91.10.2528 · Cited by 842
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
Thummel, K. E., & Wilkinson, G. R. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.389 · Cited by 831
Pekkanen, J., Linn, S., Heiss, G., Suchindran, C. M., Leon, A., Rifkind, B. M., & Tyroler, H. A. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006143222403 · Cited by 821
Paraoxonase and Atherosclerosis
Durrington, P. N., Mackness, B., & Mackness, M. I. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.21.4.473 · Cited by 818
New insights into the pharmacodynamic and pharmacokinetic properties of statins
Corsini, A., Bellosta, S., Baetta, R., Fumagalli, R., Paoletti, R., & Bernini, F. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00045-5 · Cited by 796
Self-citationManagement of Dyslipidemia in Adults With Diabetes
Haffner, S. M. (1998) · Diabetes Care · doi:10.2337/diacare.21.1.160 · Cited by 786
HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia
Oates, J. A., Wood, A. J. J., & Grundy, S. M. (1988) · New England Journal of Medicine · doi:10.1056/nejm198807073190105 · Cited by 758
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Serruys, P. W. J. C. (2002) · JAMA · doi:10.1001/jama.287.24.3215 · Cited by 719
Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review
Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., & Sadee, W. (2001) · JAMA · doi:10.1001/jama.286.18.2270 · Cited by 705
Reaven, G. M., Chen, Y. D., Jeppesen, J., Maheux, P., & Krauss, R. M. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116541 · Cited by 690
Lau, W. C., Waskell, L. A., Watkins, P. B., Neer, C. J., Horowitz, K., Hopp, A. S., Tait, A. R., Carville, D. G. M., Guyer, K. E., & Bates, E. R. (2003) · Circulation · doi:10.1161/01.cir.0000047060.60595.cc · Cited by 688
Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)
MAAS Investigators (1994) · The Lancet · doi:10.1016/s0140-6736(94)92082-6 · Cited by 647
Blankenhorn, D. H., Azen, S. P., Kramsch, D. M., Mack, W. J., Cashin-Hemphill, L., Hodis, H. N., DeBoer, L. W. V., Mahrer, P. R., Masteller, M. J., Vailas, L. I., et al. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-10-199311150-00002 · Cited by 637
Cerivastatin and Reports of Fatal Rhabdomyolysis
Staffa, J. A., Chang, J., & Green, L. (2002) · New England Journal of Medicine · doi:10.1056/nejm200202143460721 · Cited by 626
Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II)
Crouse, J. R., Byington, R. P., Bond, M. G., Espefand, M. A., Craven, T. E., Sprinkle, J. W., McGovern, M. E., & Furberg, C. D. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80580-3 · Cited by 609
Update: Clinically Significant Cytochrome P‐450 Drug Interactions
Michalets, E. L. (1998) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1998.tb03830.x · Cited by 597
Athyros, V. G., Papageorgiou, A. A., Mercouris, B. R., Athyrou, V. V., Symeonidis, A. N., Basayannis, E. O., Demitriadis, D. S., & Kontopoulos, A. G. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125000787 · Cited by 533
Waters, D., Higginson, L., Gladstone, P., Kimball, B., Le May, M., Boccuzzi, S. J., & Lespérance, J. (1994) · Circulation · doi:10.1161/01.cir.89.3.959 · Cited by 499
Gagné, C., Bays, H. E., Weiss, S. R., Mata, P., Quinto, K., Melino, M., Cho, M., Musliner, T. A., & Gumbiner, B. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02774-1 · Cited by 495
Turner, R., Cull, C., Holman, R., & United Kingdom Prospective Diabetes Study Group (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-1_part_2-199601011-00011 · Cited by 465
Evidence that triglycerides are an independent coronary heart disease risk factor
Cullen, P. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01127-9 · Cited by 462
Risk for Myopathy With Statin Therapy in High-Risk Patients
Ballantyne, C. M., Corsini, A., Davidson, M. H., Holdaas, H., Jacobson, T. A., Leitersdorf, E., März, W., Reckless, J. P. D., & Stein, E. A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.5.553 · Cited by 453
Self-citationWenke, K., Meiser, B., Thiery, J., Nagel, D., von Scheidt, W., Steinbeck, G., Seidel, D., & Reichart, B. (1997) · Circulation · doi:10.1161/01.cir.96.5.1398 · Cited by 444
Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy
Pierce, L. R. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450010075034 · Cited by 428
HMG-CoA Reductase Inhibitors and the Risk of Hip Fractures in Elderly Patients
Wang, P. S. (2000) · JAMA · doi:10.1001/jama.283.24.3211 · Cited by 416
Ballantyne, C. M., Olsson, A. G., Cook, T. J., Mercuri, M. F., Pedersen, T. R., & Kjekshus, J. (2001) · Circulation · doi:10.1161/hc5001.100624 · Cited by 416
Sacks, F. M., Tonkin, A. M., Shepherd, J., Braunwald, E., Cobbe, S., Hawkins, C. M., Keech, A., Packard, C., Simes, J., Byington, R., et al. (2000) · Circulation · doi:10.1161/01.cir.102.16.1893 · Cited by 388
Comparison of statins in hypertriglyceridemia
Stein, E. A., Lane, M., & Laskarzewski, P. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00041-1 · Cited by 386 · cited 1×
“Statins that lower LDL cholesterol levels effectively have a similar effect on triglyceride levels, but it is essential that the patients are hypercholesterolemic as well as triglyceridemic [132,133].”
BackgroundRisk factors for accelerated atherosclerosis in renal transplant recipients
Kasiske, B. L. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90302-6 · Cited by 358
Lipoprotein Metabolism and Renal Failure
Attman, P.-O., Samuelsson, O., & Alaupovic, P. (1993) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80030-8 · Cited by 355
Fichtenbaum, C. J., Gerber, J. G., Rosenkranz, S. L., Segal, Y., Aberg, J. A., Blaschke, T., Alston, B., Fang, F., Kosel, B., & Aweeka, F. (2002) · AIDS · doi:10.1097/00002030-200203080-00008 · Cited by 338
Efficacy and long-term adverse effect pattern of lovastatin
Tobert, J. A. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90004-5 · Cited by 335
Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
Martínez, E., Conget, I., Lozano, L., Casamitjana, R., & Gatell, J. M. (1999) · AIDS · doi:10.1097/00002030-199905070-00009 · Cited by 321
Antidepressant-Induced Sexual Dysfunction
Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a195 · Cited by 320
Herd, J. A., Ballantyne, C. M., Farmer, J. A., Ferguson, J. J., Jones, P. H., West, M. S., Gould, K. L., & Gotto, A. M. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00346-9 · Cited by 315
(1993) · JAMA · doi:10.1001/jama.269.4.505 · Cited by 315
HYPERLIPIDEMIA IN SOLID ORGAN TRANSPLANTATION
Kobashigawa, J. A., & Kasiske, B. L. (1997) · Transplantation · doi:10.1097/00007890-199702150-00001 · Cited by 314
McKenney, J. M. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510330050033 · Cited by 306
Mackness, M. I., Abbott, C., Arrol, S., & Durrington, P. N. (1993) · Biochemical Journal · doi:10.1042/bj2940829 · Cited by 305
HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients
Seliger, S. L., Weiss, N. S., Gillen, D. L., Kestenbaum, B., Ball, A., Sherrard, D. J., & Stehman-Breen, C. O. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00109.x · Cited by 294
The genetic basis of variability in drug responses
Roden, D. M., & George Jr, A. L. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd705 · Cited by 292
Range of serum cholesterol values in the population developing coronary artery disease
Kannel, W. B. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)80474-3 · Cited by 289
Mechanistic Studies on Metabolic Interactions between Gemfibrozil and Statins
Prueksaritanont, T., Zhao, J. J., Ma, B., Roadcap, B. A., Tang, C., Qiu, Y., Liu, L., Lin, J. H., Pearson, P. G., & Baillie, T. A. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1042 · Cited by 287
Lipid abnormalities in renal disease
Appel, G. (1991) · Kidney International · doi:10.1038/ki.1991.22 · Cited by 286
Kantola, T., Kivistö, K. T., & Neuvonen, P. J. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90151-5 · Cited by 286
Tonelli, M., Moy, L., Sacks, F. M., Kiberd, B., Curhan, G., & for the Cholesterol and Recurrent Events (CARE) Trial Investigators (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-2-200301210-00010 · Cited by 278 · cited 1×
“Thus, a retrospective investigation of 3716 patients with end stage renal disease (ESRD) showed that statin use was independently associated with a 36% reduction in the risk of cardiovascular mortality [217], while results from the recent CARE (Cholesterol and Recurrent Events) study showed pravastatin treatment reduc…”
BackgroundPharmacology of competitive inhibitors of HMg-CoA reductase
Corsini, A. (1995) · Pharmacological Research · doi:10.1016/1043-6618(95)80042-5 · Cited by 277
Self-citationCoronary risk factors, endothelial function, and atherosclerosis: A review
Vogel, R. A. (1997) · Clinical Cardiology · doi:10.1002/clc.4960200505 · Cited by 256
Khan, M. A., St. Peter, J. V., & Xue, J. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.708 · Cited by 250
Simvastatin Initiated Early After Heart Transplantation: 8-Year Prospective Experience
Wenke, K., Meiser, B., Thiery, J., Nagel, D., von Scheidt, W., Krobot, K., Steinbeck, G., Seidel, D., & Reichart, B. (2003) · Circulation · doi:10.1161/01.cir.0000043241.32523.ee · Cited by 247
Herrington, D. M., Vittinghoff, E., Lin, F., Fong, J., Harris, F., Hunninghake, D., Bittner, V., Schrott, H. G., Blumenthal, R. S., & Levy, R. (2002) · Circulation · doi:10.1161/01.cir.0000019406.74017.b2 · Cited by 235
Soma, M. R., Donetti, E., Parolini, C., Mazzini, G., Ferrari, C., Fumagalli, R., & Paoletti, R. (1993) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.13.4.571 · Cited by 225
Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease
Rapaport, E. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500040071040 · Cited by 224
Christians, U., Jacobsen, W., & Floren, L. C. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00016-3 · Cited by 220
Tolman, K. G. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02355-x · Cited by 214
Cardiovascular morbidity and risk factors in renal transplant patients
Aakhus, S., Dahl, K., & Wideroe, T. (1999) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/14.3.648 · Cited by 214
THE EFFECT OF PRAVASTATIN ON ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION-A PILOT STUDY1
Katznelson, S., Wilkinson, A. H., Kobashigawa, J. A., Wang, X.-M., Chia, D., Ozawa, M., Zhong, H.-P., Hirata, M., Cohen, A. H., Terasaki, P. I., et al. (1996) · Transplantation · doi:10.1097/00007890-199605270-00010 · Cited by 209
Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities
Henry, K., Melroe, H., Huebesch, J., Hermundson, J., & Simpson, J. (1998) · The Lancet · doi:10.1016/s0140-6736(98)00022-1 · Cited by 207
LIPID ABNORMALITIES IN CYCLOSPORINE-PREDNISONE-TREATED RENAL TRANSPLANT RECIPIENTS
VATHSALA, A., WEINBERG, R. B., SCHOENBERG, L., GREVEL, J., GOLDSTEIN, R. A., VAN BUREN, C. T., LEWIS, R. M., & KAHAN, B. D. (1989) · Transplantation · doi:10.1097/00007890-198907000-00009 · Cited by 200
The Contribution of P‐glycoprotein to Pharmacokinetic Drug‐Drug Interactions
Yu, D. K. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922012006 · Cited by 199
Influence of Low HDL on Progression of Coronary Artery Disease and Response to Fluvastatin Therapy
Ballantyne, C. M., Herd, J. A., Ferlic, L. L., Dunn, J. K., Farmer, J. A., Jones, P. H., Schein, J. R., & Gotto, A. M. (1999) · Circulation · doi:10.1161/01.cir.99.6.736 · Cited by 198
Mayer, K. H., Dube, M. P., Sprecher, D., Henry, W. K., Aberg, J. A., Torriani, F. J., Hodis, H. N., Schouten, J., Levin, J., Myers, G., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/317429 · Cited by 197
Sacks, F. M., Tonkin, A. M., Craven, T., Pfeffer, M. A., Shepherd, J., Keech, A., Furberg, C. D., & Braunwald, E. (2002) · Circulation · doi:10.1161/01.cir.0000012918.84068.43 · Cited by 188
Comparative Tolerability of the HMG-CoA Reductase Inhibitors
Farmer, J. A., & Torre-Amione, G. (2000) · Drug Safety · doi:10.2165/00002018-200023030-00003 · Cited by 181
Boyd, R. A., Stern, R. H., Stewart, B. H., Wu, X., Reyner, E. L., Zegarac, E. A., Randinitis, E. J., & Whitfield, L. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/009127000004000112 · Cited by 179
HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein
Wang, E.-J., Casciano, C. N., Clement, R. P., & Johnson, W. W. (2001) · Pharmaceutical Research · doi:10.1023/a:1011036428972 · Cited by 176
Drug Therapy for Hypercholesterolemia and Dyslipidemia
de Ferranti, S. D. (2008) · Handbook of Pediatric Cardiovascular Drugs · doi:10.1007/978-1-84628-953-8_13 · Cited by 175
The interaction of diltiazem with lovastatin and pravastatin*
Azie, N. E., Brater, D. C., Becker, P. A., Jones, D. R., & Hall, S. D. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90067-4 · Cited by 174
Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes
Niemi, M., Cascorbi, I., Timm, R., Kroemer, H. K., Neuvonen, P. J., & Kivistö, K. T. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.127495 · Cited by 173
RISK FACTORS PREDICTING CHRONIC REJECTION OF RENAL ALLOGRAFTS
ISONIEMI, H., NURMINEN, M., TIKKANEN, M. J., WILLEBRAND, E. V., KROGERUS, L., AHONEN, J., EKLUND, B., HÖCKERSTEDT, K., SALMELA, K., & HÄYRY, P. (1994) · Transplantation · doi:10.1097/00007890-199401000-00013 · Cited by 169
Igel, M., Sudhop, T., & von Bergmann, K. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100329 · Cited by 169
Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity
Kuhn, F. E., Mohler, E. R., Satler, L. F., Reagan, K., Lu, D. Y., & Rackley, C. E. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90274-o · Cited by 165
The human drug metabolizing cytochromes P450
Wrighton, S. A., VandenBranden, M., & Ring, B. J. (1996) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf02353474 · Cited by 164
Clinical Pharmacokinetics of Fluvastatin
Scripture, C. D., & Pieper, J. A. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140040-00003 · Cited by 163
Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety
Shepherd, J. (1995) · European Heart Journal · doi:10.1093/eurheartj/16.1.5 · Cited by 157
Ichihara, A., Hayashi, M., Ryuzaki, M., Handa, M., Furukawa, T., & Saruta, T. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.8.1513 · Cited by 156
Persistent Hyperlipidemia in Renal Transplant Patients
KASISKE, B. L., & UMEN, A. J. (1987) · Medicine · doi:10.1097/00005792-198707000-00003 · Cited by 154
Use of Statins and Blood Pressure Control in Treated Hypertensive Patients with Hypercholesterolemia
Borghi, C., Prandin, M. G., Costa, F. V., Bacchelli, S., Esposti, D. D., & Ambrosioni, E. (2000) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200004000-00006 · Cited by 151
van Heeswijk, R., Veldkamp, A., Mulder, J., Meenhorst, P. L., Lange, J. M. A., Beijnen, J. H., & Hoetelmans, R. (2002) · Antiviral Therapy · doi:10.1177/135965350200600401 · Cited by 150
Fischer, V., Johanson, L., Heitz, F., Tullman, R. H., Graham, E., Baldeck, J. P., & Robinson, W. T. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14919-7 · Cited by 149
Hsyu, P., Schultz-Smith, M. D., Lillibridge, J. H., Lewis, R. H., & Kerr, B. M. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.12.3445-3450.2001 · Cited by 144
Sposito, A. C., Mansur, A. D. P., Coelho, O. R., Nicolau, J. C., & Ramires, J. A. F. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00132-0 · Cited by 141
Hsu, I., Spinier, S. A., & Johnson, N. E. (1995) · Annals of Pharmacotherapy · doi:10.1177/106002809502907-818 · Cited by 140
HIV Protease Inhibitors Stimulate Hepatic Triglyceride Synthesis
Lenhard, J. M., Croom, D. K., Weiel, J. E., & Winegar, D. A. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.12.2625 · Cited by 140
The interaction of diltiazem with simvastatin
Mousa, O., Brater, D. C., Sundblad, K. J., & Hall, S. D. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.104609 · Cited by 138
Rhabdomyolysis from the Coadministration of Lovastatin and the Antifungal Agent Itraconazole
Lees, R. S., & Lees, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331015 · Cited by 136
Mulder, A. B., van Lijf, H. J., Bon, M. A. M., van den Bergh, F. A. J. T. M., Touw, D. J., Neef, C., & Vermes, I. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(01)25429-0 · Cited by 136
Tonolo, G., Melis, M. G., Formato, M., Angius, M. F., Carboni, A., Brizzi, P., Ciccarese, M., Cherchi, G. M., & Maioli, M. (2000) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2000.00735.x · Cited by 135
Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin
Gruer, P. J. K., Vega, J. M., Mercuri, M. F., Dobrinska, M. R., & Tobert, J. A. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00442-7 · Cited by 130
Åsberg, A., Hartmann, A., Fjeldså, E., Bergan, S., & Holdaas, H. (2001) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2001.10415.x · Cited by 127
The MRC/BHF Heart Protection Study: preliminary results.
Collins, R., Peto, R., & Armitage, J. (2002) · PubMed · Cited by 127
Austin, M. A., & Edwards, K. L. (1996) · Current Opinion in Lipidology · doi:10.1097/00041433-199606000-00010 · Cited by 126
Gellman, J., Ezekowitz, M. D., Sarembock, I. J., Azrin, M., Nochomowitz, L. E., Lerner, E., & Haudenschild, C. C. (1991) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(91)90735-r · Cited by 126
Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors
Garnett, W. R. (1995) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/52.15.1639 · Cited by 125
Bottorff, M., & Hansten, P. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.15.2273 · Cited by 123
Effect of fluconazole on plasma fluvastatin and pravastatin concentrations
Kantola, T., Backman, J. T., Niemi, M., Kivistö, K. T., & Neuvonen, P. J. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000127 · Cited by 122
Rhabdomyolysis due to interaction of simvastatin with mibefradil
Schmassmann-Suhijar, D., Bullingham, R. E. S., Gasser, R., Schmutz, J., & Haefeli, W. E. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78613-x · Cited by 118
Rhabdomyolysis After Taking Atorvastatin With Gemfibrozil
Duell, P. B., Connor, W. E., & Illingworth, D. R. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00907-7 · Cited by 118
Regazzi, M. B., Iacona, I., Campana, C., Raddato, V., Lesi, C., Perani, G., Gavazzi, A., & Viganò, M. (1993) · PubMed · Cited by 114
Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition
Sahi, J., Black, C. B., Hamilton, G. A., Zheng, X., Jolley, S., Rose, K. A., Gilbert, D., LeCluyse, E. L., & Sinz, M. W. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.4.439 · Cited by 113 · cited 1×
“Recent evidence from in vitro experiments suggests that both rosiglitazone and pioglitazone may behave as inducers of the CYP3A4 system [195].”
BackgroundWiesbauer, F., Kaun, C., Zorn, G., Maurer, G., Huber, K., & Wojta, J. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704454 · Cited by 111
Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial
Holdaas, H., Jardine, A. G., Wheeler, D. C., Brekke, I. B., Conlon, P. J., Fellström, B., Hammad, A., Holme, I., Isoniemi, H., Moore, R. H., et al. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00010.x · Cited by 110
Asztalos, B. F., Horvath, K. V., McNamara, J. R., Roheim, P. S., Rubinstein, J. J., & Schaefer, E. J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00149-1 · Cited by 109
Lutucuta, S., Ballantyne, C. M., Elghannam, H., Gotto, A. M., & Marian, A. J. (2001) · Circulation Research · doi:10.1161/hh0901.090301 · Cited by 108
In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin*
Transon, C., Leemann, T., Vogt, N., & Dayer, P. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90054-3 · Cited by 106
Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease
Eichstädt, H. W., Eskötter, H., Hoffmann, I., Amthauer, H., & Weidinger, G. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(05)80033-5 · Cited by 106
Rhabdomyolysis Associated with Concomitant Use of Atorvastatin and Cyclosporine
Maltz, H. C., Balog, D. L., & Cheigh, J. S. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.19039 · Cited by 104
Pharmacokinetics of the combination of fluvastatin and gemfibrozil
Spence, J. D., Muñoz, C. E., Hendricks, L., Latchinian, L., & Khouri, H. E. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(05)80024-4 · Cited by 102
Drug–Induced Hepatitis Associated With Anticytoplasmic Organelle Autoantibodies
Homberg, J., Abuaf, N., Helmy-Khalil, S., Biour, M., Poupon, R. Y., Islam, S., Darnis, F., Vg, L., Opolon, P., Beaugrand, M., et al. (1985) · Hepatology · doi:10.1002/hep.1840050504 · Cited by 102
Lemaître, R. N., Furberg, C. D., Newman, A. B., Hulley, S. B., Gordon, D. J., Gottdiener, J. S., McDonald, R. H., & Psaty, B. M. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.16.1761 · Cited by 101
Herrington, D. M., Werbel, B. L., Riley, W. A., Pusser, B. E., & Morgan, T. M. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00128-x · Cited by 99
Drug interactions and the statins.
Herman, R. J. (1999) · Europe PMC (PubMed Central) · Cited by 98
Hamilton‐Craig, I. (2001) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2001.tb143683.x · Cited by 97
Drug Interactions of Lipid-Altering Drugs
Bays, H. E., & Dujovne, C. A. (1998) · Drug Safety · doi:10.2165/00002018-199819050-00003 · Cited by 96
Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis
Wanner, C., for Die Deutsche Diabetes Dialyse Studie Investigators, Krane, V., Ruf, G., März, W., & Ritz, E. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.07158.x · Cited by 96
THE MRC/BHF HEART PROTECTION STUDY: PRELIMINARY RESULTS
Owen, O. G. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11192.x · Cited by 95
THE EFFECTS OF LIPID-LOWERING AGENTS ON ACUTE RENAL ALLOGRAFT REJECTION1, 2
Kasiske, B. L., Heim-Duthoy, K. L., Singer, G. G., Watschinger, B., Germain, M. J., & Bastani, B. (2001) · Transplantation · doi:10.1097/00007890-200107270-00009 · Cited by 94
Gegick, C. G., & Altheimer, M. D. (2001) · Endocrine Practice · doi:10.4158/ep.7.3.162 · Cited by 89
Naoumova, R. P., Marais, A. D., Mountney, J., Firth, J. C., Rendell, N. B., Taylor, G. W., & Thompson, G. R. (1996) · Atherosclerosis · doi:10.1016/0021-9150(95)05649-1 · Cited by 89
Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis
Wanner, C., Hörl, W. H., Luley, C. H., & Wieland, H. (1991) · Kidney International · doi:10.1038/ki.1991.92 · Cited by 89
Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety
Gavish, D., Leibovitz, E., Shapira, I., & Rubinstein, A. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00646.x · Cited by 89
Fluvastatin with and without niacin for hypercholesterolemia
Jacobson, T. A., Chin, M. M., Fromell, G. J., Jokubaitis, L. A., & Amorosa, L. F. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90088-4 · Cited by 88
Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes
Yeo, K. R., & Yeo, W. W. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2001.01386.x · Cited by 86
Leitersdorf, E., Eisenberg, S., Eliav, O., Friedlander, Y., Berkman, N., Dann, E., Landsberger, D., Sehayek, E., Meiner, V., & Wurm, M. (1993) · PubMed · Cited by 86
Pharmacokinetics of Fluvastatin and Specific Drug Interactions
Smith, H. T., Jokubaitis, L. A., Troendle, A. J., Hwang, D. S., & Robinson, W. T. (1993) · American Journal of Hypertension · doi:10.1093/ajh/6.11.375s · Cited by 86
Saltissi, D., Morgan, C., Rigby, R., & Westhuyzen, J. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.30547 · Cited by 86
Pharmacological interactions of statins
Paoletti, R., Corsini, A., & Bellosta, S. (2002) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(02)00002-8 · Cited by 85
Self-citationBocan, T. M. A., Mazur, M. J., Mueller, S. B., Brown, E. Q., Sliskovic, D. R., O'Brien, P. M., Creswell, M. W., Lee, H. H., Uhlendorf, P. D., Roth, B. D., et al. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90198-8 · Cited by 85
o, G. C., Más, R., ndez, L. F., Illnait, J., Mesa, M., Alvarez, E., & Lezcay, M. (2003) · Drugs & Aging · doi:10.2165/00002512-200320020-00006 · Cited by 85
Hyperlipidaemia in renal transplantation—risk factor for long‐term graft outcome
Dimény, E., Wahlberg, J. A., Lithell, H., & Fellström, B. (1995) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1995.tb01748.x · Cited by 85
The APOE locus and the pharmacogenetics of lipid response
Ordovas, J. M., & Mooser, V. (2002) · Current Opinion in Lipidology · doi:10.1097/00041433-200204000-00001 · Cited by 83
Maximizing the Cost-effectiveness of Lipid-Lowering Therapy
Jacobson, T. A., Schein, J. R., Williamson, A., & Ballantyne, C. M. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.18.1977 · Cited by 82
Apolipoprotein-B-Containing Lipoproteins and the Progression of Renal Insufficiency
Samuelsson, O. G., Aurell, M., Knight‐Gibson, C., Alaupovic, P., & Attman, P. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000187210 · Cited by 82
Rhabdomyolysis associated with lovastatin and erythromycin use.
Spach, D. H., Bauwens, J. E., Clark, C. D., & Burke, W. G. (1991) · PubMed Central · Cited by 81
Marian, A. J., Safavi, F., Ferlic, L. L., Dunn, J. K., Gotto, A. M., & Ballantyne, C. M. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00535-5 · Cited by 80
THE PREVALENCE OF HYPERLIPIDEMIA IN RENAL TRANSPLANT RECIPIENTS
Bittar, A. E., Ratcliffe, P. J., Richardson, A. J., Raine, A. E. G., Jones, L. A., Yudkin, P., Carter, R., Mann, J. I., & Morris, P. J. (1990) · Transplantation · doi:10.1097/00007890-199012000-00018 · Cited by 80
Pontrelli, L., Parris, W. E., Adeli, K., & Cheung, R. C. (2002) · Metabolism · doi:10.1053/meta.2002.30510 · Cited by 80
Statins and progressive renal disease
Buemi, M., Senatore, M., Corica, F., Aloisi, C., Romeo, A., Cavallaro, E., Floccari, F., Tramontana, D., & Frisina, N. (2001) · Medicinal Research Reviews · doi:10.1002/med.10000 · Cited by 79
Penzak, S. R., Chuck, S. K., & Stajich, G. V. (2000) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.13.1066.35033 · Cited by 78
Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis
Ballantyne, C. M., Pazzucconi, F., Pintó, X., Reckless, J. P., Stein, E. A., McKenney, J. B., Bortolini, M., & Chiang, Y. T. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80001-1 · Cited by 74
Pleiotropic effects of statins: do they matter?
Gotto, A. M., & Farmer, J. A. (2001) · Current Opinion in Lipidology · doi:10.1097/00041433-200108000-00004 · Cited by 74
Rhabdomyolysis Associated With Simvastatin–Gemfibrozil Therapy
Tal, A., RAJESHAWARI, M., & Isley, W. L. (1997) · Southern Medical Journal · doi:10.1097/00007611-199705000-00018 · Cited by 73
Side effects of statins: hepatitis versus “transaminitis”—myositis versus “CPKitis”
Dujovne, C. A. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02356-1 · Cited by 73
Holdaas, H., Fellström, B., Holme, I., Nyberg, G., Fauchald, P., Jardine, A. G., Grönhagen‐Riska, C., Madsen, S., Neumayer, H. ‐., Cole, E., et al. (2001) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182670100800202 · Cited by 71
Hyperlipidemia under treatment with proteinase inhibitors
Segerer, S., Bogner, J. R., Walli, R., Loch, O., & Goebel, F. D. (1999) · Infection · doi:10.1007/bf02560501 · Cited by 69
Renal Dysfunction Does Not Alter the Pharmacokinetics or LDL‐Cholesterol Reduction of Atorvastatin
Stern, R. H., Yang, B. ‐., Horton, M. W., Moore, S., Abel, R. B., & Olson, S. C. (1997) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1997.tb05629.x · Cited by 69
Lipid abnormalities in end stage renal disease
Oda, H. (1998) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/13.suppl_1.45 · Cited by 67
Kaul, D. R., Cinti, S. K., Carver, P. L., & Kazanjian, P. H. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.4.281.30937 · Cited by 67
Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil
van Puijenbroek, E., du Buf-Vereijken, P. W. G., Spooren, P. F. M. J., & van Doormaal, J. J. (1996) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1996.48879000.x · Cited by 67
Impact and management of hyperlipidemia posttransplantation.
Fellström, B. (2000) · PubMed · Cited by 66
Pauciullo, P., Borgnino, C., Paoletti, R., Mariani, M., & Mancini, M. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)00379-8 · Cited by 64
Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis.
Kanathur, N., Mathai, M. G., Byrd, R. P., Fields, C. L., & Roy, T. M. (2001) · PubMed · Cited by 63
Rhabdomyolysis due to probable interaction between simvastatin and ritonavir
Cheng, C. H., Miller, C., Lowe, C., & Pearson, V. E. (2002) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/59.8.728 · Cited by 63
Acute Cholestatic Hepatitis Associated With Pravastatin
Hartleb, M., Rymarczyk, G., & Januszewski, K. (1999) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01091.x · Cited by 62
Rhabdomyolysis and Satin Therapy: Relevance to the Elderly
Sica, D. A., & Gehr, T. W. B. (2002) · The American Journal of Geriatric Cardiology · doi:10.1111/j.1076-7460.2002.01422.x · Cited by 62
Bray, P. F., Cannon, C. P., Goldschmidt‐Clermont, P. J., Moyé, L. A., Pfeffer, M. A., Sacks, F. M., & Braunwald, E. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01677-0 · Cited by 62
The ALLHAT Lipid Lowering Trial—Less Is Less
Pasternak, R. C. (2002) · JAMA · doi:10.1001/jama.288.23.3042 · Cited by 60
Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease
Attman, P., Alaupovic, P., & Samuelsson, O. G. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.07104.x · Cited by 60
Interactions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects
Prueksaritanont, T., Vega, J. M., Zhao, J. J., Gagliano, K., Kuznetsova, O., Musser, B. J., Amin, R. D., Liu, L., Roadcap, B. A., Dilzer, S. C., et al. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010311 · Cited by 60
Mikhailidis, D. P., & Wierzbicki, A. S. (2000) · Current Medical Research and Opinion · doi:10.1185/0300799009117018 · Cited by 60
Why some patients respond poorly to statins and how this might be remedied
Thompson, G. R., O'Neill, F., & Seed, M. (2002) · European Heart Journal · doi:10.1053/euhj.2001.3071 · Cited by 59
Mostaza, J. M., Gomez, M. V., Gallardo, F. G., Salazar, M. L., Martín-Jadraque, R., Celemín, L. P., González-Maqueda, I., & Martín-Jadraque, L. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00529-x · Cited by 57
Effect of Fluvastatin on Lipids and Fibrinolysis in Coronary Artery Disease
Bevilacqua, M., Bettica, P. U., Milani, M., Vago, T., Rogolino, A. A., Righini, V., Santoli, E., & Norbiato, G. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00684-4 · Cited by 57
Sbarouni, E., Kyriakides, Z. S., & Kremastinos, D. T. H. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00413-6 · Cited by 56
IMPACT OF SERUM LIPIDS ON LONG-TERM GRAFT AND PATIENT SURVIVAL AFTER RENAL TRANSPLANTATION1
Bumgardner, G. L., Wilson, G. A., Tso, P. L., Henry, M. L., ELKHAMMAS, E. A., Davies, E. A., Qiu, W., & Ferguson, R. M. (1995) · Transplantation · doi:10.1097/00007890-199560120-00008 · Cited by 56
Simvastatin in nephrotic syndrome
Olbricht, C. J., for the Simvastatin In Nephrotic Syndrome Study Group, Wanner, C., Thiery, J., & Basten, A. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.07128.x · Cited by 55
Hyperlipidemia in kidney disease: causes and consequences
Sahadevan, M., & Kasiske, B. L. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200205000-00009 · Cited by 55
Winkler, K., Abletshauser, C., Hoffmann, M. M., Friedrich, I., Baumstark, M. W., Wieland, H., & März, W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020370 · Cited by 55
Jardine, A. G., & Holdaas, H. (1999) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.1999.00252.x · Cited by 54
Single‐Dose Pharmacokinetics of Pravastatin and Metabolites in Patients with Renal Impairment
Halstenson, C. E., Triscari, J., DeVault, A., Shapiro, B., Keane, W., & Pan, H. (1992) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1992.tb03816.x · Cited by 54
Hypertension and ischaemic heart disease in renal transplant recipients
Raine, A. E. G. (1995) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/10.supp1.95 · Cited by 54
Gheith, O. A. A., Sobh, M. A. K., Mohamed, K. E.-S., El-Baz, M. A., El-Husseini, F., Gazarin, S. S., Ahmed, H. A.-E.-H., Rasem, M. W., & Amer, G. M. (2002) · The Nephron journals/Nephron journals · doi:10.1159/000065021 · Cited by 53
Research works printed but not linked: 10
- Farmer JA,Torre-Amione G. Comparative tolerability of the HMG-CoAreductase inhibitors. Drug Saf 2000; 108: 351-352.
- Shek A,Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35: 908-917. · doi:10.1345/aph.10315 · Paper page
- Kanathur N,Mathai MG,Byrd RP Jr, et al. Simvastatindiltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001; 94: 339-341.
- Lee AJ,Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001; 35: 26-31. · doi:10.1345/aph.10177 · Paper page
- Thompson GR. Poor responders to statins:Apotential target for stanol esters. Eur Heart J Suppl 1991; 1(Suppl S): S114-S117.
- Gruer PJ,Vega JM,Mercuri MF,Dobrinska MR,Tobert JA. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999; 84: 811-815. · DOI
- Peces R,Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron 2001; 89: 117-118. · DOI
- Regazzi MB,Iacona I,Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporinAin transplant recipients. Transplant Proc 1993; 25: 2732-2734.
- Rozenbaum W,Molina JM,Delfraissy JF, et al. Improvement of lipodystrophy in HIV-1 infected subjects switching from 2NRTI/PI to 2NRTI/abacavir (French substudy, CNA30017). 7th Conference on Retroviruses and Opportunistic Infections; Jan. 3-Feb. 2, 2000; San Francisco, California. Abstract 47.
- Fichtenbaum C,Gerber J,Rosenkranz S, et al. Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors. Presented at the 7th Conference on Retroviruses and Opportunistic Infections. Jan. 30-Feb. 2, 2000; San Francisco, California.
Cited by
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Self-citationSafety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions
Bellosta, S., Paoletti, R., & Corsini, A. (2004) · Circulation · doi:10.1161/01.cir.0000131519.15067.1f · Cited by 578
Self-citationClinical Perspectives of Statin-Induced Rhabdomyolysis
Antons, K. A., Williams, C. D., Baker, S. K., & Phillips, P. S. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.02.007 · Cited by 238
Mason, R. P., Walter, M. F., Day, C. A., & Jacob, R. F. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.008 · Cited by 160
The nephrotoxic effects of HAART
Izzedine, H., Harris, M., & Perazella, M. A. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.142 · Cited by 156
Metadata
- Authors
- Corsini, A.
- Affiliations
- University of Milan (IT)
- Corresponding author
- Corsini, Alberto
- ORCID
- Corsini, Alberto
- Venue
- Cardiovascular Drugs and Therapy
- Published
- 2003-05
- Volume
- 17
- Issue
- 3
- Pages
- 265-285
- ISSN
- 0920-3206 (ISSN-L)
- 1573-7241
- OpenAlex
- W2191544621
- Cited by
- 82
- References
- 286
- Citations by year
- 2025: 1 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 4 · 2017: 4 · 2016: 1 · 2015: 2 · 2013: 5 · 2012: 2
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cardiovascular Drugs and Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- statins, drug safety, high cardiovascular risk, lipid-lowering therapy, drug interactions, myotoxicity, coronary artery disease, dyslipidemia, diabetes mellitus, hypertension, nephrotic syndrome, HIV, transplant recipients, elderly patients, statin pharmacokinetics
- MeSH terms
- Aged, Aged, 80 and over, Cardiovascular Diseases, Clinical Trials as Topic, Coronary Disease, Diabetes Mellitus, Type 2, Humans, Hyperlipidemias, Hypertension, Kidney Failure, Chronic, Rhabdomyolysis, Transplantation, HIV-1, HIV Infections, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.